Storia in 2 fonti

MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents - MapLight Therapeutics (NASDAQ:MP

MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.

Raccontata da

endpoints.news

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents - MapLight Therapeutics (NASDAQ:MP

MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.

originale

endpoints.news1 mese fa

MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment

MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication but improved irritability in teenagers.

Leggi questa versione → originale

Timeline cronologica

lunedì 22 giugno 2026·endpoints.news
MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment
MapLight plans other meet with the FDA after its autism drug ML-004 missed its Phase 2 primary endpoint on social communication but improved irritability in teenagers.
lunedì 22 giugno 2026·benzinga.com
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents - MapLight Therapeutics (NASDAQ:MP
MapLight's ML-004 misses its main autism study goal but showed notable irritability improvements in adolescents.